A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Inclusion Criteria: * Advanced malignant solid tumors for which no curative therapy exists that has recurred or pgrogressed following standard therapy * Eighteen years of age or above * Able to understand and sign an informed consent (or have a legal representative who is able to do so) * Measurable disease according to RECIST v1.1 * ECOG Performance Score of 0 or 1 * Adequate bone marrow, hepatic, renal and cardiac function * Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-141 Exclusion Criteria: * Active infection or fever \> 38.5°C during screening visits or on the first scheduled day of dosing * Symptomatic CNS disease * Received other recent antitumor therapy * Pregnant or breast feeding